David McCann, MD
Ophthalmology · Missoula, MTNPI 1669573713
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Alcon at 30.4% of the total. Reporting peaked in 2024 at $159 and has fallen 69.0% since, to $49 in 2025. That places this record below the midpoint for ophthalmology clinicians in MT, where the typical reported total is $374.
Across 17 payments — averaging $23.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$122
- Bristol Myers Squibb$65
- Amgen$64
- AbbVie$57
- UCB, Inc.$50
- Rxsight Inc$45
What the payments were for
- Food & beverage$403100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 8 | $122 |
| Bristol Myers Squibb | 1 | $65 |
| Amgen | 3 | $64 |
| AbbVie | 3 | $57 |
| UCB, Inc. | 1 | $50 |
| Rxsight Inc | 1 | $45 |
How this compares
$403 in reported general payments places this provider in the 50th percentile of 52 ophthalmology providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 302 | $3,315 |
| Latanoprost | 260 | $3,312 |
| Timolol Maleate | 132 | $1,529 |
| Prednisolone Acetate | 41 | $1,356 |
| ErythromycinErythromycin Base | 60 | $763 |
| Ketorolac Tromethamine | 23 | $760 |
| Brimonidine Tartrate | 51 | $580 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 23 | $407 |
| Ciprofloxacin Hcl | 30 | $306 |
| Ofloxacin | 15 | $175 |
| Doxycycline Hyclate | 15 | $77 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Missoula
- Jefferson BerrymanMissoula$11K
- Jacek KotowskiMissoula$981
- Scott GuessMissoula$890
- Roger FurlongMissoula$723
- Chad NedrudMissoula$659
- Rick NeumeisterMissoula$140
- Todd MurdockMissoula$136
- Brian SippyMissoula$53
- Michael PetersonMissoula$29
- Richelle StillwagonMissoula$24
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.